Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231348 · ClinicalTrials.gov registry record · Phase 4
Nefazodone in the Treatment of Social Phobia
A Phase 4 study of Social Anxiety Disorder (SAD), sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00231348 is a Phase 4 study of Social Anxiety Disorder (SAD) that has completed, run by Emory University. The registered enrollment target is 24 participants, below the 198-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00231348, a Phase 4 study of Social Anxiety Disorder (SAD), has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).
Conditions Studied
Interventions
- DRUG Nefazodone
Study Locations (1)
Georgia
- Emory University Depatment of Psychiatry and Behavioral Sciences - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Est. Completion | 2000-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00231348
The ClinicalTrials.gov registry entry for NCT00231348 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (88% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Social Anxiety Disorder (SAD) appearing as the primary indexed condition, and to 1 intervention - of which Nefazodone is the first listed.
NCT00231348 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT00231348 about?
NCT00231348 is a clinical study titled "Nefazodone in the Treatment of Social Phobia". The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).
What is the current status of trial NCT00231348?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. Estimated completion is 2000-04.
What conditions does trial NCT00231348 study?
This clinical trial studies the following conditions: Social Anxiety Disorder (SAD).
What interventions are being tested in trial NCT00231348?
The interventions under investigation include: Nefazodone (DRUG).
Who is sponsoring clinical trial NCT00231348?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00231348 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder (SAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stepped Care Treatment for Anxiety Resilience
RECRUITING · NA
-
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
RECRUITING · Phase 3
-
A Study of NTX-1472 in Social Anxiety Disorder
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.